Clinical trial · Observational
Non-invasive MRI Subclassification of Heptocellular Carcinoma - HepCaSt-Study
NCT05202015CI-TRIAL-00056081HepCaStunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Non-invasive MRI subclassification of Heptocellular Carcinoma - HepCaSt-Study
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HCC | — | UNRESOLVED | — |
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| MRI | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- HCC subtype (WHO 5)
- timeFrame
- Jan 2022 - Jul 2024
- description
- Positive identification of imaging parameters / Imaging Biomarkers correlating with one of the HCC-subtypes.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Patients with hisopathologically confirmed HCC and MRI in domo with the standard high-end MRI Primovist study protocol. Exclusion Criteria: Unmet inclusion criteria. MRI contraindications. Patients declines.
References
Publications (0)
Data not yet available
No reference posted for this study.